¼¼°è ¾Ï »ý°Ë ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®
Cancer Biopsy Market Forecasts to 2030 - Global Analysis By, Product (Instruments, Kits and Consumables and Other Products), Type (Tissue Biopsies, Liquid Biopsies, Surgical Biopsies and Other Types), Application, End User and By Geography
»óǰÄÚµå : 1403480
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,797,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,333,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,870,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,476,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¾Ï »ý°Ë ¼¼°è ½ÃÀåÀº 2023³â¿¡ 266¾ï ´Þ·¯¸¦ Â÷ÁöÇß°í ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 20%·Î ¼ºÀåÇØ 2030³â¿¡´Â 954¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

¾Ï »ý°ËÀº ¾Ï¼¼Æ÷ÀÇ Á¸Àç, ¼ºÁú, Ư¡À» Á¶»çÇϱâ À§ÇØ Àǽɽº·´°Å³ª ÀÌ»óÇÑ Áõ½Ä, ¸ÕÁö, º´º¯¿¡¼­ ÀÛÀº Á¶Á÷ »ùÇÃÀ» äÃëÇÏ¿© °Ë»çÇÏ´Â ÀÇ·á óġÀÔ´Ï´Ù. ¾Ï »ý°ËÀº ¾Ï Àü¹®ÀÇ ¹× ÀÇ·á Àü¹®°¡¿¡°Ô Á¤È®ÇÏ°í »ó¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇϰí Á¤È®ÇÑ Áø´ÜÀ» ³»¸®°í °¢ ȯÀÚÀÇ ¾Ï Ư¼º¿¡ µû¶ó ¸ÂÃãÇü Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ µµ¿òÀ̵Ǵ ±âº»ÀûÀÎ °ÍÀÔ´Ï´Ù.

¹Ì±¹ÀÇ À¯¹æ¾Ï Åë°è¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¿©¼ºÀÇ ¾à 8¸í Áß 1¸íÀÌ Ä§À±¼º À¯¹æ¾ÏÀ» ¾Î°í ÀÖ½À´Ï´Ù.

¾Ï ÀÌȯÀ² »ó½Â

°í·ÉÈ­, ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, ȯ°æÆø·Î, À¯ÀüÀû ¼ÒÀÎ µî ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ¸·Î Áø´ÜµÇ´Â »ç¶÷ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¾ÏÀº ¼¼°èÀÇ °Ç°­ ¹®Á¦·Î °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÏ°í ½Ã±â ÀûÀýÇÑ ¾Ï Áø´Ü¿¡ ´ëÇÑ ¼ö¿äµµ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. »ý°Ë ÀýÂ÷´Â º´¸®ÇÐÀû ºÐ¼®À» À§ÇØ Á¶Á÷ »ùÇÃÀ» äÃëÇÏ¿© ¾Ï Áø´ÜÀ» È®Á¤Çϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ¾Ï ÀÌȯÀ²ÀÇ »ó½ÂÀº ½ÃÀå ¼ö¿ä¸¦ °¡¼ÓÈ­ÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù.

³ôÀº ºñ¿ë

Áø´Ü ºñ¿ëÀÇ ³ôÀÌ´Â ¼¼°è ¾Ï »ý°Ë ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¾Ï Áø´Ü °Ë»ç´Â °íºñ¿ëÀ̸ç ȯÀÚ °¡Á·¿¡°Ô ´õ¿í °æÁ¦Àû ºÎ´ãÀ» °­ÇÕ´Ï´Ù. ±×·¯¹Ç·Î ÀÌ·¯ÇÑ °Ë»ç´Â º¸Çè Àû¿ë ¹ÛÀÇ Áß·ù °è±Þ ȯÀÚÃþ¿¡ Á¢±ÙÇÒ ¼ö ¾ø½À´Ï´Ù. ¶ÇÇÑ ¸¹Àº ºñ°ø°³ ȸ»ç´Â ¾Ï Áø´Ü °ü·Ã ºñ¿ëÀ» ÁöºÒÇÏÁö ¾ÊÀ¸¹Ç·Î Áø´Ü ºñ¿ëÀÌ ³ô¾Æ ¾Ï ½ºÅ©¸®´× ±â¼úÀÇ »ç¿ëÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Áøº¸

±â¼úÀÇ Áøº¸·Î ¹Ì¼¼Ä§ ÈíÀÔ¹ý(FNA), ÄÚ¾î »ý°Ë(CNB), ³»½Ã°æ »ý°Ë µî Àúħ½À »ý°Ë ±â¼úÀÌ °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÀýÂ÷´Â ´õ ÀÛÀº Àý°³Ã¢°ú ¹Ù´ÃÀ» »ç¿ëÇÏ¿© Á¶Á÷ »ùÇÃÀ» äÃëÇϱ⠶§¹®¿¡ ±âÁ¸ÀÇ °³º¹ ¼ö¼ú¿¡ ÀÇÇÑ »ý°Ë¿¡ ºñÇØ ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀ̰í ÇÕº´ÁõÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ȸº¹ »¡¸® ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº ½ÃÀå ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

ÀÎ½Ä ºÎÁ·

ƯÁ¤ Áö¿ªÀ̳ª Àα¸Ãþ¿¡¼­´Â ¾Ï Áø´Ü¿¡ À־ÀÇ »ý°ËÀÇ Áß¿äÇÑ ¿ªÇÒ¿¡ ´ëÇØ¼­, ÀÏ¹Ý ÁÖ¹ÎÀ̳ª ÇコÄɾî Àü¹®°¡ÀÇ »çÀÌ¿¡¼­ ÃæºÐÇÑ ÀνÄÀ» ¾òÀ» ¼ö ¾ø¾ú½À´Ï´Ù. ȯÀÚ´Â Á¾¾çÀÇ ¼ºÁú°ú Ư¡À» °áÁ¤Çϴµ¥ »ý°Ë ÀýÂ÷ÀÇ Á߿伺À» ÃæºÐÈ÷ ÀÌÇØÇÏÁö ¸øÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Çʼö Áø´Ü °Ë»ç¸¦ ¹Þ´Â °ÍÀ» ¸Á¼³À̰ųª ½È¾îÇÒ ¼ö ÀÖ½À´Ï´Ù. ·Î ¿¬°áµË´Ï´Ù. ±× °á°ú, ÀÎ½Ä ºÎÁ·ÀÌ ½ÃÀåÀÇ Å« ¾ïÁ¦¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19ÀÇ ÃâÇöÀº ¾Ï »ý°Ë ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. À¯ÇàÀÇ Ãʱ⠴ܰ迡¼­´Â »çȸÀû °Å¸®¸¦ µÎ´Â Á¶Ä¡ÀÇ °á°ú·Î º´¿ø ÁøÂûÀÌ ¾ö°ÝÈ÷ Á¦ÇѵǾú°í ÀÀ±Þ ȯÀÚ ¸¸ Çã¿ëµÇ¾úÁö¸¸ ÀÌ´Â ½ÃÀå È®´ë¿¡ ¾Ç¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. °Ô´Ù°¡ ÆÒµ¥¹Í ÀÌÈÄ ½Å±â¼úÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí Á¶»ç ´ë»ó ½ÃÀå¿¡ »õ·Î¿î Àü¸ÁÀÌ ¿­·È½À´Ï´Ù.

¿¹Ãø±â°£ µ¿¾È ¼ö¼ú»ý°ËºÐ¾ß°¡ ÃÖ´ëÈ­µÉ Àü¸Á

¼ö¼ú »ý°Ë ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼ö¼ú »ý°ËÀº Àý°³ ¶Ç´Â ¼ö¼ú ÀýÂ÷ Áß¿¡ Á¶Á÷ »ùÇÃÀ» Á¦°ÅÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ¹æ¹ýÀº º´¸® Àǻ簡 Á¾¾çÀÇ Æ¯Â¡, ¾Ç¼ºµµ, È®»ê Á¤µµ¸¦ ºÐ¼®ÇÒ ¼ö ÀÖµµ·Ï Á¤¹Ð °Ë»ç¸¦ À§ÇØ Å« Á¶Á÷ Ç¥º»ÀÌ ÇÊ¿äÇÑ °æ¿ì¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ¾Ï »ý°Ë¿¡¼­´Â Á¤È®ÇÑ Áø´Ü°ú Ä¡·á °èȹÀ» À§ÇØ ÃæºÐÇÑ Á¶Á÷ Ç¥º»À» ¾ò´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Àåºñ ºÎ¹®ÀÌ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±â±¸ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àåºñ´Â Á¤È®Çϰí È¿°úÀûÀÎ »ý°Ë ÀýÂ÷¸¦ ÃËÁøÇϰí Á¤È®ÇÑ ¾Ï Áø´Ü ¹× Ä¡·á °áÁ¤¿¡ ±â¿©ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â±¸¿¡´Â ±âÁ¸ÀÇ »ý°Ë ¹Ù´Ã, »ý°Ë Áý°Ô, ³·Àº ħ½À ÀýÂ÷¸¦ À§ÇØ ¼³°èµÈ Ư¼ö ±â±¸ µî °Ë»ç¿ë Á¶Á÷ »ùÇÃÀ» äÃëÇÏ´Â µ¥ »ç¿ëµÇ´Â ±¤¹üÀ§ÇÑ ±â±¸°¡ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ÃÊÀ½ÆÄ, MRI, CT ½ºÄ³³Ê¿Í °°Àº °í±Þ ¿µ»ó Áø´Ü Àåºñ´Â »ý°ËÀ» ¼öÇàÇϴ ƯÁ¤ ºÎÀ§¿¡ ÀÓ»óÀǸ¦ À¯µµÇϰí Ç¥ÀûÀ» Á¤È®ÇÏ°Ô »ùÇøµÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª:

¾Æ½Ã¾ÆÅÂÆò¾çÀº °Ç°­ °ü¸® ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ Áøº¸¿Í ¾ÏÀÇ Á¶±â ¹ß°ß ¹× Á¶±â Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Áß±¹, Àεµ, ÀϺ»°ú °°Àº ±¹°¡¿¡¼­´Â ¾Ï ȯÀÚÀÇ À¯º´·üÀÌ »ó½ÂÇϰí ÀÖÀ¸¸ç Áø´Ü °æ·ÎÀÇ Áß¿äÇÑ ¿ä¼Ò·Î »ý°Ë ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÌ Áö¿ªÀº ¾Ï Ä¡·áÀÇ °³¼±°ú ÀÇÇÐ ¿¬±¸ÀÇ À°¼º¿¡ ÈûÀ» ½ñ°í ÀÖÀ¸¸ç, ¼¼°èÀÇ ¾Ï »ý°Ë ½ÃÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

ºÏ¹Ì´Â °íµµÀÇ ÇコÄɾî ÀÎÇÁ¶ó, ¾Ï ȯÀÚÀÇ ³ôÀº À¯º´·ü, ±â¼ú Çõ½Å¿¡ÀÇ Àû±ØÀûÀÎ ´ëó¿¡ ÀÇÇØ ¿¹Ãø±â°£ Áß¿¡ À¯ÀÍÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ºÏ¹Ì¿¡¼­´Â ¼ö¼ú »ý°Ë, ¹Ù´Ã »ý°Ë, ¾×ü »ý°Ë µî ´Ù¾çÇÑ »ý°Ë ±â¼úÀÌ ¾Ï Áø´Ü ¹× Ä¡·á °èȹ¿¡ ´ëÇÑ Á¤È®Çϰí Á¾ÇÕÀûÀÎ Á¤º¸¸¦ ¾ò±â À§ÇØ ³Î¸® äÅõǾú½À´Ï´Ù. ¶ÇÇÑ, ÷´Ü ¿µ»ó ±â¼ú, ºÐÀÚÁø´Ü ¹× ³·Àº ħ½À »ý°Ë ¹æ¹ýÀÇ Ã¤ÅÃÀº Áø´Ü Á¤È®µµ¿Í ȯÀÚ °á°ú¸¦ Çâ»ó½ÃŰ´Â ÀÌ Áö¿ªÀÇ Çå½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¹«·á ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µå´Â ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¾Ï »ý°Ë ½ÃÀå : Á¦Ç°º°

Á¦6Àå ¼¼°èÀÇ ¾Ï »ý°Ë ½ÃÀå : À¯Çüº°

Á¦7Àå ¼¼°èÀÇ ¾Ï »ý°Ë ½ÃÀå : ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ ¾Ï »ý°Ë ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ¼¼°èÀÇ ¾Ï »ý°Ë ½ÃÀå : Áö¿ªº°

Á¦10Àå ÁÖ¿ä ¹ßÀü

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Cancer Biopsy Market is accounted for $26.6 billion in 2023 and is expected to reach $95.4 billion by 2030 growing at a CAGR of 20% during the forecast period. A cancer biopsy is a medical procedure involving the removal and examination of a small tissue sample from a suspicious or abnormal growth, lump, or lesion to determine the presence, nature, and characteristics of cancer cells. Cancer biopsies are fundamental to providing accurate and detailed information for oncologists and healthcare professionals, helping them formulate precise diagnoses and develop tailored treatment plans based on the unique characteristics of each patient's cancer.

According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer.

Market Dynamics:

Driver:

Rising cancer incidence

Cancer continues to be a global health concern, with increasing numbers of individuals being diagnosed with various types of cancer due to various factors such as aging populations, lifestyle changes, environmental exposures, and genetic predisposition. As the number of cancer cases increases, the demand for accurate and timely cancer diagnosis also grows. Biopsy procedures play a crucial role in confirming cancer diagnoses by obtaining tissue samples for pathological analysis. Therefore, rising cancer incidence is a significant factor accelerating market demand.

Restraint:

High cost

The high cost of diagnosis is one of the main factors anticipated to impede the growth of the global cancer biopsy market. Cancer diagnostic tests are highly costly, which puts additional financial strain on patient families. Thus, these tests are not affordable for middle-class patient population that is not covered under any insurance. Additionally, a number of private insurance companies do not pay for cancer diagnosis-related expenses, which means that the high cost of diagnosis restricts the use of cancer screening technologies.

Opportunity:

Technological advancements

Technological advancements have led to the development of minimally invasive biopsy techniques such as fine needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsy. These techniques use smaller incisions or needles to obtain tissue samples, reducing patient discomfort, minimizing the risk of complications, and enabling faster recovery compared to traditional open surgical biopsies. These factors enhance market demand.

Threat:

Lack of awareness

In certain regions or demographic segments, there is a lack of sufficient awareness among both the general population and healthcare professionals about the critical role of biopsies in cancer diagnosis. Patients may not fully comprehend the importance of biopsy procedures in determining the nature and characteristics of tumours, leading to hesitancy or reluctance to undergo these essential diagnostic tests. As a result, a lack of awareness is a significant restraint hampering the market.

COVID-19 Impact

The emergence of COVID-19 had a significant impact on the cancer biopsy market. Hospital visits were severely restricted during the early stages of the pandemic as a result of social distancing measures; only patients with emergencies were permitted, which had a negative effect on the market's expansion. Moreover, following the pandemic, there was a rise in the adoption of new technologies, which opened up new prospects for the market under study.

The surgical biopsies segment is expected to be the largest during the forecast period

The surgical biopsies segment is estimated to hold the largest share. A surgical biopsy involves the removal of a tissue sample through an incision or during a surgical procedure. This method is commonly employed when larger tissue specimens are needed for thorough examination, allowing pathologists to analyze the tumour's characteristics, grade, and extent of spread. In cancer biopsies, surgical biopsies are frequently utilized for tumours located in deep or challenging-to-access areas, where obtaining an adequate tissue sample is crucial for accurate diagnosis and treatment planning.

The instruments segment is expected to have the highest CAGR during the forecast period

The instruments segment is anticipated to have lucrative growth during the forecast period. Instruments play a pivotal role in facilitating precise and effective biopsy procedures, contributing to accurate cancer diagnoses and treatment decisions. These instruments encompass a wide range of devices used to obtain tissue samples for examination, including traditional biopsy needles, biopsy forceps, and specialized tools designed for minimally invasive procedures. Additionally, advanced imaging instruments such as ultrasound, MRI, and CT scanners are integral to guiding clinicians to the specific site for biopsy, ensuring targeted and accurate sampling.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rapid advancements in healthcare infrastructure and a growing focus on early cancer detection and treatment. With a rising prevalence of cancer cases in countries like China, India, and Japan, there is an increasing demand for biopsy procedures as a crucial component of the diagnostic pathway. Moreover, the region's commitment to improving cancer care and fostering medical research positions it as a key contributor to the global cancer biopsy market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to advanced healthcare infrastructure, a high prevalence of cancer cases, and a robust focus on technological innovation. In North America, various biopsy techniques, including surgical, needle, and liquid biopsies, are widely employed to obtain precise and comprehensive information for cancer diagnosis and treatment planning. Additionally, the adoption of cutting-edge imaging technologies, molecular diagnostics, and minimally invasive biopsy procedures underscores the region's commitment to enhancing diagnostic accuracy and patient outcomes.

Key players in the market:

Some of the key players in the Cancer Biopsy Market include Becton, Dickinson and Company, Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics, Inc., Hologic, Inc., Neo Genomics, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., QIAGEN N.V. and Sysmex Corporation.

Key Developments:

In May 2023, Partnership between Thermo Fisher Scientific and BRIN to enable and enhance the country's national research and innovation infrastructure and capability.

In March 2023, Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.

In Jan 2023, Philips a global leader in health technology, and Masimo, a global medical technology company, announced an expansion of their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1™ advanced health tracking watch.

Products Covered:

Types Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Cancer Biopsy Market, By Product

6 Global Cancer Biopsy Market, By Type

7 Global Cancer Biopsy Market, By Application

8 Global Cancer Biopsy Market, By End User

9 Global Cancer Biopsy Market, By Geography

10 Key Developments

11 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â